The B.1.617.1 variant with combined L452R and E484Q mutations was identified in COVID-19 cases in India, raising concerns about potential impacts on vaccine efficacy.
To the Editor—The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in places where the virus is uncontained poses a global threat from the perspective of public health and vaccine efficacy. Peng et al [1] recently reported on the increased transmissibility with the newly emerged Variant of Concern (VOC) (20C/S:452R and 20C/S:452R) with the L452R mutation in San Francisco. We report the immunological characteristics of a Variant under Investigation (VUI) B.1.617.1, playing a critical role in the current surge of coronavirus disease 2019 (COVID-19) in the western state of Maharashtra, India. Several SARS-CoV-2 variants—B.1.1.7, B.1.351, and B.1.1.28.1—have been reported in India during 2021 [2, 3]. We had sequenced 146 nasopharyngeal/oropharyngeal swabs of COVID-19 cases [4]. Among these, 15 sequences had a combination of L452R and E484Q mutations, which raised concern as both are found in the receptor-binding domain (RBD) of the spike protein. However, the combined effect of these mutations is still unknown.
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2021) conducted a letter in COVID-19 (n=146). SARS-CoV-2 variant sequencing was evaluated on Presence of combined L452R and E484Q mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: